September 29, 2020

The Niche

Knoepfler lab stem cell blog

CiRA (Center for iPS cell Research and Application

3 min read

A researcher working at Kyoto University has reportedly engaged in misconduct leading to an institutional request for retraction of a paper from the journal Stem Cell Reports. The paper in question appears to have rather large-scale problems: “Kohei Yamamizu, a specially appointed assistant professor at the university’s Center for iPS Cell Research and Application, falsified all six main figures in the paper that claimed he had succeeded in generating a brain structure in vitro using iPS cells, according to Kyoto University.” The Center for iPS Cell …Read More

1 min read

Where is the field of IPS cells going and how will this impact the overall field of stem cell-based regenerative medicine? Nobel Laureate Shinya Yamanaka, the discoverer of IPS cells, gave a really interesting recent interview to Nikkei that provides some fascinating insights into the future of this exciting technology that is now more than a decade old. For simplicity I have indicated top highlights from the Yamanaka interview below as bullet points. More IPS cell trials are on track to start as soon as 2018 …Read More

2 min read

It’s been a long road, but the first ever IPS cell clinical study in humans is starting up again in a new incarnation. You might say it has been regenerated in a novel form. Masayo Takahashi (高橋 政代) first started the pioneering IPS cell study a few years back in 2014, but it ended up getting put on hold in the summer of 2015 in the midst of changing regs in Japan and the discovery of some mutations in the IPS cell derivatives. About …Read More

1 min read

Some good news today as the pioneering induced pluripotent stem (IPS) cell trial led by Dr. Masayo Takahashi will resume. This clinical study with a focus on macular degeneration has been on hold for quite some time due to regulatory changes in Japan. There had also been concerns over mutations in the 2nd patient’s IPS cell product. As previous signs had indicated, the new clinical work will have an allogeneic focus, most likely drawing IPS cells from a bank. According to a Japan Times …Read More